이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aptevo Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Aptevo Therapeutics 의 총 주주 지분은 $6.1M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $17.6M 및 $11.5M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$10.25m
주식	US$6.10m
총 부채	US$11.53m
총 자산	US$17.63m

최근 재무 상태 업데이트

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

재무 상태 분석

단기부채: APVO 의 단기 자산 ( $12.1M )이 단기 부채( $6.3M ).

장기 부채: APVO 의 단기 자산( $12.1M )이 장기 부채( $5.2M ).

부채 대 자본 내역 및 분석

부채 수준: APVO 부채가 없습니다.

부채 감소: APVO 는) 부채 대 자기자본 비율이 49.6% 였던 5년 전과 비교하여 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: APVO 은 마지막 보고 무료 현금 흐름을 기준으로 5 개월 동안 충분한 현금 활주로를 보유하고 있지만 이후 추가 자본을 조달했다.

예측 현금 활주로: APVO 은 잉여현금흐름추정을 기준으로 5 개월 동안 충분한 현금 활주로를 확보할 것으로 예상되지만 이후 추가 자본을 조달했습니다.

Aptevo Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Recent updates

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기